Contents

Search

Souvenaid; Fortasyn Connect

Apparently proprietary blend of omega-3 fatty acids, phospholipids, choline, selenium, uridine, folic acid, vitamin B12, vitamin B6, vitamin C, vitamin E Indications: - improves some cognitive outcomes in patients with mild Alzheimer's disease (AD) Dosage: - once-a-day drink taken with breakfast Adverse effects: - well tolerated, apparently safe [2] Mechanism of action: - hypothesis/marketing pitch is that Souvenaid improves brain synapse formation & function [4] - allegedly preserves organisation of brain networks in patients with mild AD* [3] - allegedly slows hippocampal atrophy * demonstrated with 'advanced EEG analysis, using the mathematical framework of graph theory' Clinical trials: - LipiDiDiet trial failed to show benefit in early AD [5]

General

medical food

References

  1. Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
  2. Olde Rikkert MG, Verhey FR, Blesa R et al Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open- label extension study. J Alzheimers Dis. 2015;44(2):471-80. doi: 10.3233/JAD-141305. PMID: 25322923
  3. de Waal H, Stam CJ, Lansbergen MM, Wieggers RL et al The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. PLoS One. 2014 Jan 27;9(1):e86558. PMID: 24475144 Free PMC Article
  4. Scheltens P, Twisk JW, Blesa R et al Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012;31(1):225-36. doi: 10.3233/JAD-2012-121189. PMID: 22766770
  5. George J, Nutrient Drink Fails to Aid Cognition in Early Alzheimer's. Researchers suggest study may have been underpowered. MedPage Today. No 03, 2017 - Soininen H, Solomon A, Visser PJ et al 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology. Oct 30, 2017 PMID: 29097166 Free full text http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30332-0/fulltext

Components

ascorbate; ascorbic acid; vitamin C choline fatty acid, omega-3 (Epanova) folic acid; folate; vitamin B9 phospholipid pyridoxine (a vitamin B6) selenium [Se] uridine vitamin B12; cobalamin vitamin E